• EMA Calls for Withdrawal of Marketing Authorizations for Oral Meprobamate-Containing Medicines

    The European Medicines Agency (EMA) today called on EU national regulatory authorities, including France, UK and Italy, to withdraw their respective Marketing Authorizations (MA) for oral meprobamate-containing medications. The medication has been associated with severe side effects including overdose, coma and death. Meprobamate is a prescription sedative medicine used to treat anxiety, alcohol withdrawal, migraine attacks, disgestive disorders, muscle tensions, muscle ...